| NCT Number | NCT05985655 |
| Lead Sponsor | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. |
| Conditions | Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC) |
| Enrollment | 230 participants |
| Start Date | 2023-07-06 |
| Primary Completion | 2028-01 (estimated) |
| Study Completion | 2028-05 (estimated) |
| Updated on ClinicalTrials.gov | 2026-08-13 |